Clinical Trial Update: Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of lapatinib and trastuzumab for HER2-negative/HER2-mutant metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Tykerb (lapatinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Breast Neoplasms | Phase 2 | Status: WITHDRAWN